SCHEMBL29447356

SCHEMBL29447356

COc1cccc(CN2CCCCC2)c1

nearest known ligand 0.77

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
SIGMAR1 Q99720 3/20 0.77
ALDH1A1 P00352 3/20 0.72
KDM4E B2RXH2 2/20 0.72
HRH3 Q9Y5N1 1/20 0.69
CASP1 P29466 1/20 0.64
CASP4 P49662 1/20 0.64
CASP5 P51878 1/20 0.64
GAA P10253 1/20 0.63
MEN1 O00255 2/20 0.59
KMT2A Q03164 2/20 0.59
SMN1; SMN2 Q16637 2/20 0.58
TDP1 Q9NUW8 1/20 0.58
MAPT P10636 1/20 0.58
TSHR P16473 1/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1883482 1.00 SIGMAR1 (0.77) SIGMAR1ALDH1A1KDM4EHRH3CASP1
Hydrochloric Acid SCHEMBL16825187 0.98 SIGMAR1 (0.74) SIGMAR1ALDH1A1KDM4EHRH3CASP1
SCHEMBL3162705 0.98 SIGMAR1 (0.79) SIGMAR1ALDH1A1KDM4EHRH3CASP1
SCHEMBL30774908 0.95 SIGMAR1 (0.79) SIGMAR1ALDH1A1KDM4EHRH3CASP1
SCHEMBL19206069 0.92 SIGMAR1 (0.70) SIGMAR1ALDH1A1KDM4EHRH3CASP1
SCHEMBL28186295 0.91 SIGMAR1 (0.90) SIGMAR1ALDH1A1KDM4ECASP1CASP4
SCHEMBL20804357 0.91 SIGMAR1 (0.90) SIGMAR1ALDH1A1KDM4ECASP1CASP4
Benzylamine SCHEMBL28105111 0.91 SIGMAR1 (0.74) SIGMAR1ALDH1A1KDM4EHRH3CASP1
SCHEMBL24495483 0.89 DRD4 (0.68) SIGMAR1ALDH1A1KDM4EHRH3CASP1
SCHEMBL19206085 0.88 SIGMAR1 (0.64) SIGMAR1ALDH1A1KDM4EHRH3CASP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11787785-B2 Pyrazolopyridine derivatives and uses thereof NOVARTIS AG (CH) 2023-10-17 US claimed
US-20230108325-A1 Pyrazolopyridine Derivatives and Uses thereof NOVARTIS AG (CH) 2023-04-06 US claimed
US-20250282762-A1 PYRAZOLOPYRIDINE DERIVATIVES AND USES THEREOF NOVARTIS AG (CH) 2025-09-11 US disclosed
US-12252482-B2 Pyrazolopyridine derivatives and uses thereof NOVARTIS AG (CH) 2025-03-18 US disclosed
US-20250002479-A1 PYRAZOLOPYRIDINE DERIVATIVES AND USES THEREOF NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. 2025-01-02 US disclosed
US-12172984-B2 Pyrazolopyridine derivatives and uses thereof NOVARTIS AG (CH) 2024-12-24 US disclosed
US-11787785-B2 Pyrazolopyridine derivatives and uses thereof NOVARTIS AG (CH) 2023-10-17 US disclosed
US-20230321067-A1 DOSING REGIMEN COMPRISING 3-(1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH INC. 2023-10-12 US disclosed
US-20230108325-A1 Pyrazolopyridine Derivatives and Uses thereof NOVARTIS AG (CH) 2023-04-06 US disclosed
US-11299490-B2 Benzenesulfonamide compounds and their use as therapeutic agents XENON PHARMACEUTICALS INC. (CA) 2022-04-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11787785-B2 Pyrazolopyridine derivatives and uses thereof HBZ, ZFX, WIZ SIGMAR1 2433/4885ALDH1A1 1243/4885KDM4E 2746/4885
US-12172984-B2 Pyrazolopyridine derivatives and uses thereof HBZ, ZFX, WIZ SIGMAR1 2433/4885ALDH1A1 1243/4885KDM4E 2746/4885
US-12252482-B2 Pyrazolopyridine derivatives and uses thereof HBZ, ZFX, WIZ SIGMAR1 2433/4885ALDH1A1 1243/4885KDM4E 2746/4885
US-20250282762-A1 PYRAZOLOPYRIDINE DERIVATIVES AND USES THEREOF HBZ, ZFX, WIZ SIGMAR1 2433/4885ALDH1A1 1243/4885KDM4E 2746/4885
US-20230321067-A1 DOSING REGIMEN COMPRISING 3-(1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES IKZF1, IKZF2, IKZF3 SIGMAR1 3897/4885ALDH1A1 2551/4885KDM4E 335/4885
US-20230108325-A1 Pyrazolopyridine Derivatives and Uses thereof HBZ, ZFX, WIZ SIGMAR1 2433/4885ALDH1A1 1243/4885KDM4E 2746/4885
US-11299490-B2 Benzenesulfonamide compounds and their use as therapeutic agents SCN1A, SCN1B, SCN2B SIGMAR1 3293/4885ALDH1A1 2797/4885KDM4E 1252/4885
US-20250002479-A1 PYRAZOLOPYRIDINE DERIVATIVES AND USES THEREOF HBZ, ZFX, WIZ SIGMAR1 2433/4885ALDH1A1 1243/4885KDM4E 2746/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.